Five organic-inorganc hybrid compounds, namely, [Co-2(fcz)(4)(H2O)(4)][beta-MO8O26]center dot 5H(2)O (1), (Ni-2(fcz)4(H2O)(4)][beta-MO8O26]center dot 5H(2)O (2), [Zn-2(fcz)(4)(beta-Mo8O26)]center dot 4H(2)O (3), [CU2(fcz)(4)(beta-Mo8O26)center dot 4H(2)O (4), and [Ag-4(fcz)(4)(beta-Mo8O26)] (5), where fcz is fluconazole [2-(2,4-difluorophenyl)-1,3-di(1 H-1,2,4-triazol-1 -yl)propan-2-ol], were synthesized under hydrothermal conditions, and crystal structures of 1-5 have been determined by X-ray diffraction. In compounds 1 and 2, metal cations are linked by lluconazole ligands to form hinged chain structures and [beta-Mo8O26](4-) anions act as counterions. In compound 3, Zn(II) cations are bridged by fluconazole ligands to form 2D (4,4) networks, and each pair of these networks is linked by beta-Mo8O26](4-) anions to form a sandwich double-layer structure. In compound 4, Cu(II) cations are bridged by flucoriazole ligands to form 2D (4,4) networks, and these networks are connected by beta-Mo8O26]4- 14anions to form a 3D framework. In compound 5, Ag-1 cations and [Ag-2](2+) units are bridged by fluconazole ligands to form 2D Ag-fcz layers, and these layers are further connected by beta-Mo8O26](4-) anions to form a complicated 3D structure with the topology of (7(2) center dot 8(1))(2)(7(3) center dot 8(3)) (7(2) center dot 8(11)center dot 10(1)center dot 12(1))(2). Thermogravimetric analyses for these compounds are also discussed in detail. The complexes exhibit antitumor activity in vitro, as shown by MTT experiments.